<DOC>
	<DOCNO>NCT01534260</DOCNO>
	<brief_summary>This research do treatment option limit usually unsuccessful Acute Myeloid Leukemia ( AML ) old individual , young people disease relapse and/or proven resistant standard therapy . Subjects invited participate study examine use three drug call Sorafenib ( Nexavar ) , Vorinostat ( Zolinza ) Bortezomib ( Velcade ) treat acute myeloid leukemia .</brief_summary>
	<brief_title>Phase I/II Study Combination Sorafenib , Vorinostat , Bortezomib Treatment Acute Myeloid Leukemia With Complex- Poor-risk ( Monosomy 5/7 ) Cytogenetics FLT3-ITD Positive Genotype</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Monosomy</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>A confirmed baseline diagnosis AML revise guideline International Working Group AML include newly diagnose , relapsed refractory disease . Poorrisk complex cytogenetics profile , deletion chromosome 5 , deletion chromosome 7 , positive FLT3ITD mutation . The patient must discontinue previous therapy acute leukemia least 14 day recover acute nonhematologic side effect therapy . Hydroxyurea control peripheral blood blast count must discontinue within 24 hour prior initiation treatment . Patients must ECOG ( Zubrod ) performance status 02 Patients must adequate hepatic renal function accord protocol within one week prior treatment . Female patient must postmenopausal , surgically sterile agree use effective method contraception throughout study . Male patient , even surgically sterilize , must agree practice effective contraception throughout study . Patients must able swallow tolerate oral medication . Known central nervous system ( CNS ) leukemia . Diagnosis acute promyelocytic leukemia ( APL ) . Grade &gt; /= 2 peripheral neuropathy . Serious illness include , significant ongoing active infection , New York Heart Association ( NYHA ) Grade III IV congestive heart failure , unstable angina new onset angina myocardial infarction within past 6 month , cardiac ventricular arrhythmia require antiarrhythmic therapy , thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 3 month . Serious medical psychiatric illness/social situation opinion investigator would limit compliance study requirement . Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Active corneal erosion history abnormal corneal sensitivity test . Known suspected history severe hypersensitivity reaction tyrosine kinase inhibitor , histone deacetylase inhibitor , proteosome inhibitor , boron , mannitol . Female patient lactate positive serum pregnancy test within 72 hour initiation treatment , positive urine pregnancy test Day 1 first dose study drug . Concurrent use histone deacetylase inhibitor ( e.g . valproic acid ) prohibit except HDAC inhibitor HDACinhibitor like agent used noncancer treatment ( e.g . epilepsy ) , 14 day washout allow . Radiation therapy within 3 week randomization . Patients know HIV , know active hepatitis B C infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>